Kaneka Corporation invests in Spanish biotech company

| By | Biotechnologies, R&D

Kaneka Corporation (Tokyo, Japan) acquired a 34.8% share of AB-Biotics (Barcelona, Spain), a Spanish biotech company focusing on research, development, and distribution of its own products using lactic acid bacteria.

At the same time, Kaneka has concluded a license agreement with ABB to grant Kaneka the exclusive rights for production and sales of ABB’s products in North America (USA and Canada) and Japan.

Lactic acid bacteria have been drawing people’s attention for their effect and efficacy not only to intestinal function and immune system, but also to allergic symptoms and infectious diseases. The interest and business of dairy products such as yoghurt, functional foods and dietary supplements containing lactic acid bacteria is also rapidly increasing.

ABB possesses advanced R&D capability with more than 550 original probiotic strains extracted from human origin samples. ABB sells a wide range of clinically documented probiotics products, which improve the intestinal environment and have clear effects to decrease the risk of cardiovascular diseases, periodontal diseases, infectious diseases, etc. to health food and pharmaceutical companies worldwide.

Kaneka has been expanding its functional food business globally such as regenerative co-enzyme Q10 (Kaneka QH), polyphenol derived from licorice (Kaneka Gravonoid™) and plant-derived lactic acid bacillus, fully supported by the evidence data regarding its safety and beneficial effects to humans.

SOURCE: prnewswire.com
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.